MRJ Capital Inc. Has $3,513,000 Holdings in Amgen Inc. (AMGN)
MRJ Capital Inc. held its stake in shares of Amgen Inc. (NASDAQ:AMGN) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 20,400 shares of the medical research company’s stock at the close of the 2nd quarter. Amgen accounts for about 2.1% of MRJ Capital Inc.’s investment portfolio, making the stock its 25th biggest position. MRJ Capital Inc.’s holdings in Amgen were worth $3,513,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also modified their holdings of AMGN. TrimTabs Asset Management LLC raised its stake in Amgen by 88.9% in the 1st quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock worth $100,000 after acquiring an additional 288 shares during the last quarter. American Beacon Advisors Inc. purchased a new position in Amgen in the 1st quarter worth $106,000. Grove Bank & Trust raised its stake in Amgen by 87.4% in the 2nd quarter. Grove Bank & Trust now owns 731 shares of the medical research company’s stock worth $126,000 after acquiring an additional 341 shares during the last quarter. Enterprise Financial Services Corp raised its stake in Amgen by 18.0% in the 2nd quarter. Enterprise Financial Services Corp now owns 748 shares of the medical research company’s stock worth $129,000 after acquiring an additional 114 shares during the last quarter. Finally, Proficio Capital Partners LLC raised its stake in Amgen by 246.4% in the 1st quarter. Proficio Capital Partners LLC now owns 866 shares of the medical research company’s stock worth $134,000 after acquiring an additional 616 shares during the last quarter. Hedge funds and other institutional investors own 78.15% of the company’s stock.
A number of equities analysts recently issued reports on the company. Argus lowered Amgen from a “buy” rating to a “hold” rating and raised their target price for the stock from $175.22 to $195.00 in a research note on Wednesday, November 1st. Zacks Investment Research lowered Amgen from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Mizuho set a $198.00 target price on Amgen and gave the stock a “buy” rating in a research note on Sunday, October 29th. BMO Capital Markets restated a “market perform” rating and issued a $198.00 target price on shares of Amgen in a research note on Thursday, October 26th. Finally, Morgan Stanley reduced their target price on Amgen from $196.00 to $193.00 and set an “overweight” rating for the company in a research note on Thursday, October 26th. Thirteen research analysts have rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company’s stock. Amgen presently has an average rating of “Buy” and a consensus price target of $190.03.
In other news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $171.58, for a total transaction of $261,659.50. Following the sale, the executive vice president now directly owns 57,631 shares in the company, valued at approximately $9,888,326.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Carbonnel Francois De sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total value of $694,440.00. The disclosure for this sale can be found here. Insiders have sold a total of 7,050 shares of company stock worth $1,239,673 over the last 90 days. Insiders own 0.19% of the company’s stock.
Shares of Amgen Inc. (NASDAQ:AMGN) opened at $169.96 on Friday. The firm has a market capitalization of $123,375.77, a PE ratio of 13.51, a price-to-earnings-growth ratio of 2.46 and a beta of 1.37. The company has a debt-to-equity ratio of 1.05, a quick ratio of 5.72 and a current ratio of 6.07. Amgen Inc. has a 12-month low of $138.83 and a 12-month high of $191.10.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The company had revenue of $5.77 billion for the quarter, compared to the consensus estimate of $5.75 billion. During the same period last year, the firm earned $3.02 EPS. The firm’s revenue for the quarter was down .7% compared to the same quarter last year. equities analysts anticipate that Amgen Inc. will post 12.66 earnings per share for the current fiscal year.
Amgen announced that its board has approved a share buyback plan on Wednesday, October 25th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical research company to purchase shares of its stock through open market purchases. Stock buyback plans are often a sign that the company’s leadership believes its shares are undervalued.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Friday, November 17th will be given a dividend of $1.15 per share. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.71%. The ex-dividend date is Thursday, November 16th. Amgen’s dividend payout ratio (DPR) is presently 41.63%.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.